New valves may grow with patients and may have lower rejection rates
Researchers have found a way to take a pediatric patient’s skin cells, reprogram the skin cells to function as heart valvular cells, and then use the cells as part of a tissue-engineered pulmonary valve. A proof of concept study in the September 2014 issue of The Annals of Thoracic Surgery provides more detail on this scientific development.
“Current valve replacements cannot grow with patients as they age, but the use of a patient-specific pulmonary valve would introduce a ‘living’ valvular construct that should grow with the patient. Our study is particularly important for pediatric patients who often require repeated operations for pulmonary valve replacements,” said lead author David L. Simpson, PhD, from the University of Maryland School of Medicine in Baltimore.
Dr. Simpson, senior co-author Sunjay Kaushal, MD, PhD, and colleagues designed a process to transform skin cells from a simple biopsy into cells that become an important ingredient in a tissue-engineered pulmonary valve.
The pulmonary valve is a crescent-shaped valve that lies between the heart’s right ventricle and pulmonary artery. It is responsible for moving blood from the heart into the lungs.
While the study was conducted in vitro (outside of the body), the next step will be implanting the new valves into patients to test their durability and longevity.
The Latest on: Reprogramming skin cells
via Google News
The Latest on: Reprogramming skin cells
- Research Brief: Study finds two protein pathways downregulated in postnatal hearton August 4, 2022 at 9:54 am
Published today in Stem Cell Reports, researchers from the University of Minnesota Medical School discovered two signaling pathways that are downregulated in human hearts after birth.
- Israeli scientists make model synthetic mouse embryo with stem cells - studyon August 2, 2022 at 3:07 pm
The Synthetic embryo models could also eventually become a reliable source of cells, tissues and organs for transplantation.
- Twenty-Five Years After My House Call To Dolly: What Have We Learned About Cloning And How Did We Learn It?on August 2, 2022 at 8:30 am
Twenty-five years ago, the scientific breakthrough of mammalian cloning marked a monumental moment in medicine and science. I, the only physician in the U.S. Senate at the time, journeyed to the ...
- Gaining insights into spastic paraplegiaon August 2, 2022 at 8:06 am
Rare diseases, as the name indicates, only affect a small part of the population. However, for those affected they are particularly challenging, often especially because research into such rare ...
- Researchers reprogram stem cells to uncover new genetic signatures of age-related AMDon August 2, 2022 at 7:34 am
Researchers are closer to better diagnosing and treating age-related macular degeneration (AMD) after discovering new genetic signatures of the disease by reprogramming stem cells to generate ...
- Global Stem Cell Market to Reach at US$ 25.68 billion by 2028on August 1, 2022 at 2:59 am
For example, iPSC therapies are created by taking a little amount of a patient’s blood or skin cells and reprogramming them to make new cells and tissue for transplant. As a result, future ...
- Molecular Signatures of Age-Related Macular Degeneration Identifiedon July 27, 2022 at 2:10 am
The discovery of molecular signatures of the incurable eye disease, age-related macular degeneration, could improve diagnosis and treatment.
- Clues to age-related macular degeneration revealedon July 26, 2022 at 12:51 pm
Better diagnosis and treatment of the incurable eye disease age-related macular degeneration is a step closer, thanks to the discovery of new genetic signatures of the disease.
- Genetic clues to age-related macular degeneration revealedon July 26, 2022 at 2:02 am
Their skin cells were reprogrammed to revert to stem cells called induced pluripotent stem cells, and then guided with molecular signals to become retinal pigment epithelium cells, which are the ...
- Replay Launches with $55 Million Seed to Reprogram Biology by Writing and Delivering Big DNAon July 25, 2022 at 4:03 am
Replay, a genome writing company reprogramming biology by writing and delivering big DNA, today announced its launch with $55 million in seed financing. The round was led by KKR and OMX Ventures, with ...
via Bing News